<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04629872</url>
  </required_header>
  <id_info>
    <org_study_id>MRCTA, ECFAH of FMU [2020]296</org_study_id>
    <nct_id>NCT04629872</nct_id>
  </id_info>
  <brief_title>Fingolimod in Endovascular Treatment of Ischemic Stroke</brief_title>
  <official_title>Combinating Fingolimod With Endovascular Treatment in Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ning Wang, MD., PhD.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Fujian Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proof-of concept clinical trials have indicated that the sphingosine-1-phosphate receptor&#xD;
      modulator fingolimod may be efficacious in attenuating brain inflammation and improving&#xD;
      clinical outcomes in patients with acute ischemic stroke as a single therapy beyond 4.5 hours&#xD;
      of disease onset, or in combination with alteplase within 4.5 hours of disease onset. This&#xD;
      study aim to determine whether fingolimod enhance the action of endovascular treatment for&#xD;
      acute ischemic stroke&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the grade of collateral circulation</measure>
    <time_frame>Baseline (before endovascular treatment)</time_frame>
    <description>Multiphasic contrast-enhanced CT collateral grades with six-point pial arterial filling ordinary score as established at the University of Calgary</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Stroke Inflammation</condition>
  <arm_group>
    <arm_group_label>endovascular treatment with fingolimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>endovascular treatment without fingolimod</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fingolimod</intervention_name>
    <description>Patients randomized to fingolimod will also receive oral fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is more than 3 hour prior to mechanical thrombectomy.</description>
    <arm_group_label>endovascular treatment with fingolimod</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients presenting with anterior circulation acute ischaemic stroke who are eligible&#xD;
             for mechanical thrombectomy commenced within 6-24 hours of stroke onset.&#xD;
&#xD;
          -  Patient, family member or legally responsible person depending on local ethics&#xD;
             requirements has given informed consent.&#xD;
&#xD;
          -  Patient's age is 18-80 years.&#xD;
&#xD;
          -  Arterial occlusion on internal carotid artery proximal or middle cerebral artery&#xD;
&#xD;
          -  Imaging inclusion criteria: infarct core volume between 15-70 mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing neurologic disability (a score greater than 2 on the mRS).&#xD;
&#xD;
          -  Swallowing difficulties that would prevent administration of oral fingolimod.&#xD;
&#xD;
          -  Patients with any history of bradyarrhythmia, atrioventricular block or current use of&#xD;
             beta-blockers or verapamil.&#xD;
&#xD;
          -  Patients with serious acute or chronic infection, or hepatic injury&#xD;
&#xD;
          -  Concomitant use of antineoplastic, immunosuppressive or immune modulating therapies.&#xD;
&#xD;
          -  Macular edema.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>fu ying, MD</last_name>
    <phone>13920263588</phone>
    <email>fuying1995@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <zip>350000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Fu</last_name>
      <phone>+8613920263688</phone>
      <email>fuying@fjmu.eu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 11, 2020</study_first_submitted>
  <study_first_submitted_qc>November 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>November 13, 2020</last_update_submitted>
  <last_update_submitted_qc>November 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Ning Wang, MD., PhD.</investigator_full_name>
    <investigator_title>Director of Neurology department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fingolimod Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

